Affiliations 

  • 1 Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou syylwu@live.cn
  • 2 Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
  • 3 Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 4 Cancer Center of Union Hospital, Tongji Medical College, Huzhong University of Science and Technology, Wuhan
  • 5 Department of Internal Medicine Tumor, Academy of Military Medical Sciences Affiliated Hospital (307 Hospital of PLA), Beijing
  • 6 Cancer Centre, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing
  • 7 Department of Lung Cancer, Shanghai Chest Hospital, Shanghai
  • 8 Jilin Cancer Hospital, Changchun
  • 9 Department of Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou
  • 10 Fujian Provincial Tumor Hospital, Fujian
  • 11 Nanjing Bayi Hospital, Nanjing
  • 12 Department of Lung Cancer, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing
  • 13 Department of Oncology, Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou
  • 14 Affiliated Xinan Hospital of Third Military Medical University, Chongqing
  • 15 First Affiliated Hospital, Medical School Xi'an Jiaotong University, Xi'an
  • 16 Cancer Hospital, Fudan University, Shanghai, China
  • 17 Department of Medicine, International Islamic University Malaysia, Kuala Lumpur, Malaysia
  • 18 Manila Doctors Hospital, Manila, The Philippines
  • 19 Roche (China) Holding Ltd, Shanghai, China
Ann. Oncol., 2015 Sep;26(9):1883-9.
PMID: 26105600 DOI: 10.1093/annonc/mdv270

Abstract

The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC).

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.